DISCOVER THE LATEST ADVANCEMENTS
IN MRD TESTING |
Treatment response in multiple myeloma is measured by the detection of paraprotein in the serum and/or urine, bone marrow morphology, and immunohistochemistry. However, more effective and targeted treatments are driving a need for improved disease burden assessment at a level of sensitivity beyond what conventional methods offer. New analytical tools have emerged for the assessment of minimal residual disease (MRD), offering unparalleled sensitivity to measure trace amounts of disease.1
One such tool, clonoSEQ®, is available to ION members and is the only FDA-cleared assay for the detection and monitoring of MRD in bone marrow samples from multiple myeloma or B-cell acute lymphoblastic leukemia patients.
Powered by next-generation sequencing (NGS), clonoSEQ enables identification of residual disease down to 1 cell in a million provided sufficient sample input.2 For myeloma patients, MRD-negativity at deeper sensitivity is associated with improved overall survival and progression-free survival in both the front-line and relapsed settings.3
|
clonoSEQ is available to clinicians nationwide and is covered by Medicare and national private health insurers enabling access for over 165 million individuals.
Learn how to incorporate clonoSEQ into your practice by visiting clonoSEQ.com. |